IRADIMED CORPORATION (NASDAQ:IRMD) Files An 8-K Entry into a Material Definitive Agreement

IRADIMED CORPORATION (NASDAQ:IRMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry Into a Material Definitive Agreement.

Story continues below

On March 26, 2019, Iradimed Corporation (the “Company”) entered into an amendment to the Supply Agreement (the “Amendment”) with Fukoku Co., Ltd. Dated as of January 26, 2014. Under the Amendment, the term of the Supply Agreement was extended through February 25, 2024.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment.

The Company will file the Amendment as an exhibit to its Quarterly Report on Form 10-Q for the first quarter of 2019.

About IRADIMED CORPORATION (NASDAQ:IRMD)

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

An ad to help with our costs